肺免疫预后指数与信迪利单抗治疗晚期非小细胞肺癌患者预后的相关性  

Correlation between the pulmonary immune prognostic index and prognosis of advanced non-small cell lung cancer patients treated with sintilimab

作　　者：温旭智 许春妮 洪国标[2] 骆学新[2] 陈雯微 WEN Xuzhi;XU Chunni;HONG Guobiao;LUO Xuexin;CHEN Wenwei(Department of Oncology,Yixing Hospital Affiliated to Jiangsu University,Wuxi,Jiangsu,214200;Department of Medical Oncology,the Second Hospital of Shaoxing in Zhejiang Province,Shaoxing,Zhejiang,312000)

机构地区：[1]江苏大学附属宜兴医院肿瘤科,江苏无锡214200 [2]浙江省绍兴第二医院肿瘤内科,浙江绍兴312000

出　　处：《实用临床医药杂志》2025年第3期17-21,29,共6页Journal of Clinical Medicine in Practice

基　　金：浙江省中医药科技计划项目(2023ZL185)。

摘　　要：目的分析肺免疫预后指数(LIPI)与信迪利单抗治疗晚期非小细胞肺癌(NSCLC)患者预后的相关性。方法选取145例晚期NSCLC患者作为研究对象。所有患者行信迪利单抗治疗,记录患者的临床资料。根据LIPI,将患者分为LIPI低风险组、LIPI中风险组和LIPI高风险组。分析LIPI与晚期NSCLC患者预后的相关性。筛选患者无进展生存期(PFS)和总生存期(OS)的影响因素。结果单因素分析显示,患者年龄、是否吸烟、病理类型、临床分期和LIPI是PFS的影响因素(P<0.05);年龄、病理类型、临床分期和LIPI是OS的影响因素(P<0.05)。多因素Cox回归分析显示,年龄60~70岁、年龄>70岁、腺癌、分期Ⅳ期、LIPI高风险是患者PFS预后的独立影响因素(P<0.05);年龄>70岁、分期Ⅳ期、腺癌、LIPI高风险是患者OS预后的独立影响因素(P<0.05)。LIPI低风险、中风险和高风险影响患者预后。LIPI低风险患者预后更佳,中位PFS、OS更长。结论LIPI与信迪利单抗治疗晚期NSCLC患者的预后具有相关性。LIPI低风险晚期NSCLC患者在信迪利单抗治疗中获益更多。Objective To analyze the correlation between the pulmonary immune prognostic index(LIPI)and the prognosis of patients with advanced non-small cell lung cancer(NSCLC)treated with sintilimab.Methods A total of 145 patients with advanced NSCLC were selected as study subjects.All patients received treatment with sintilimab,and their clinical baseline data were recorded.According to the LIPI score,patients were divided into low-risk,intermediate-risk,and high-risk groups.The correlation between LIPI and the prognosis of advanced NSCLC patients was analyzed.Factors influencing progression-free survival(PFS)and overall survival(OS)were identified.Results Univariate analysis showed that patient age,smoking status,pathological type,clinical stage and LIPI were factors affecting PFS(P<0.05);age,pathological type,clinical stage and LIPI were factors affecting OS(P<0.05).Multivariate Logistic regression analysis revealed that age of 60 to 70 years,age>70 years,adenocarcinoma,stageⅣand high-risk LIPI were independent prognostic factors of PFS(P<0.05);age>70 years,poor stageⅣ,adenocarcinoma and high-risk LIPI were independent prognostic factors of OS(P<0.05).LIPI influenced patient′s prognosis,with low-risk patients showing better outcomes and longer median PFS and OS.Conclusion LIPI is correlated with the prognosis of advanced NSCLC patients treated with sintilimab.Patients with a low-risk LIPI assessment benefit more from sintilimab treatment.

关 键 词：非小细胞肺癌 信迪利单抗 肺免疫预后指数 总生存期 无进展生存期 

分 类 号：R734.2[医药卫生—肿瘤] R816.4[医药卫生—临床医学] R446